All News Dicot Pharma AB

Equities

End-of-day quote NORDIC GROWTH MARKET Other stock markets 23:00:00 27/06/2024 BST			5-day change	1st Jan Change
0.379 ^SEK	-18.32%		-6.88%	+19.18%

06-06	Dicot Pharma AB Develops LIB-01 into A New Potency Drug with Improved Properties Compared to Currently Available Drugs	CI
05-06	Dicot Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Dicot Pharma: Experts from Dicot Pharma's clinical study behind submitted abstract	06-19	PU
Experts from Dicot Pharma's clinical study behind submitted abstract	06-18	AQ
LIB-01 appears to affect metabolic diseases and Dicot Pharma files new patent application	06-06	AQ
Dicot Pharma AB Develops LIB-01 into A New Potency Drug with Improved Properties Compared to Currently Available Drugs	06-06	CI
Today Dicot AB becomes Dicot Pharma AB	05-30	AQ
Dicot presents interim report Q1 2024	05-06	AQ
Dicot Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
Dicot AB has Changed its Name to Dicot Pharma AB	05-06	CI
Good safety and improved erectile function reported from Dicot's phase 1 study	04-23	AQ
Dicot AB Announces Positive Safety and Improved Efficacy Results from Phase 1 Study	04-23	CI
Dicot in preparation for clinical phase 2a trial	04-12	AQ
Reporting from Dicot's phase 1 study end of April	04-05	AQ
BioStock: Dicot's phase I study fully recruited	03-14	AQ
Recruitment completed in Dicot's phase 1 trial	03-11	AQ
Dicot AB Announces Recruitment Completed in Dicot's Phase 1 Trial	03-11	CI
Dicot's CEO tells BioStock: "Several prominent people want to be part of the journey"	02-29	AQ
Dicot AB Year-End Report 2023	02-26	AQ
Dicot AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-26	CI
BioStock: Good safety profile for Dicot's LIB-01	01-26	AQ
Positive results from the first part of Dicot's phase 1 study	01-23	AQ

No results for this search